EMEA-002964-PIP01-21

Key facts

Active substance
Casirivimab
Therapeutic area
Infectious diseases
Decision number
P/0347/2021
PIP number
EMEA-002964-PIP01-21
Pharmaceutical form(s)
  • Concentrate for solution for infusion
  • Solution for injection
Condition(s) / indication(s)
  • Prevention of Coronavirus disease 2019 (COVID-19)
  • Treatment of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
  • Subcutaneous use
  • Intravenous use
Contact for public enquiries
Regeneron Ireland DAC

Tel. +1 9148 475385
E-mail: clinicaltrials@regeneron.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating